Concerning KRAS mutations, in the ES-NSCLC setting, 40% of KRAS mutated cases harbored the p.(G12C) alteration, equal to 17% of all ES analyzed cases. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.